Atrium Therapeutics, Inc. (RNA) stock
RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.98+0.34 (+5.12%)
Close on Nov 19, 2026Market cap $119.40MP/E –Yield –
Atrium Therapeutics net income
Net income is the profit left for shareholders after every expense, interest and tax.
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$4.27M | – |
| Q2 FY2026 | Jun 30, 2026 | -$20.19M | – |
| Q1 FY2026 | Mar 31, 2026 | -$16.63M | – |
| Q3 FY2025 | Sep 30, 2025 | -$37.00K | – |
| Q2 FY2025 | Jun 30, 2025 | -$12.88M | – |
| Q1 FY2025 | Mar 31, 2025 | -$7.45M | – |
See a number that looks wrong?